Llwytho...
Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
Epidermal growth factor receptor (EGFR) is over-expressed in nearly all cases of squamous cell carcinoma of the head and neck (SCCHN), and is an important driver of disease progression. EGFR targeted therapies have demonstrated clinical benefit for SCCHN treatment. In this report, we investigated th...
Wedi'i Gadw mewn:
Prif Awduron: | , , , , , , , , , |
---|---|
Fformat: | Artigo |
Iaith: | Inglês |
Cyhoeddwyd: |
Public Library of Science (PLoS)
2014-01-01
|
Cyfres: | PLoS ONE |
Mynediad Ar-lein: | http://europepmc.org/articles/PMC4031184?pdf=render |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|